Determined to realize a future in which people with cancer live longer and better than ever before

Syndax 

Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

Syndax investment highlights

Entinostat

Combo with anti-PD-(L)1:

- Signals in Mel, NSCLC
- Ongoing NSCLC, Mel, TNBC, Ovar, CRC trials
- Multiple data readouts

FDA BTD

Combo with exemestane:

- Phase 3 data 1H18
- Japan pivotal initiated

SNDX-6352

CSF1R antibody:

- Phase 1 multiple ascending dose study ongoing
- Broad clinical dev program

NEW

Menin-MLLr inh

Onc driver specific:

- Targeting MLLr leukemias
- Preclinical dev. ongoing

Strong management team and cash position

CRC - colorectal cancer; NSCLC - non-small cell lung cancer; Mel - melanoma; TNBC - triple negative breast cancer; Ovar - ovarian cancer

Previous milestones

ENTINOSTAT (Class 1 specific HDAC inhibitor)	update	3Q17	4Q17	1H18	2H18
ENCORE 601 – Go / No go decision on Naïve NSCLC cohort	✓				
ENCORE 601 – Present biomarker analysis (Melanoma)	✓				
ENCORE 601 – Present stage 1 NSCLC data	✓				
ENCORE 601 – Go / No go decision on Stage 1 of CRC cohort					
ENCORE 601 – Present full Phase 2 results for melanoma and pre-Tx NSCLC and stage 1 results for CRC (n=13)					
E2112 - Per ECOG, complete Phase 3 enrollment; release PFS					
ENCORE 602 – Present Phase 2 results (TNBC)					

SNDX-6352 (anti-CSF-1R mAB)	update	3Q17	4Q17	1H18	2H18
SAD trial data presentation (healthy volunteers)	✓				
MAD trial data presentation (patients with solid tumors)					

ENCORE 601 / KEYNOTE 142 Recent Updates

Entinostat + KEYTRUDA®

NSCLC
PD-1/PDL-1 – naïve

NSCLC
Progressing on PD-1/PDL-1

Melanoma
Progressing on PD-1

MSS CRC
PD-1/PDL-1 – naïve

- **PD-(L)1 naïve NSCLC cohort** – Met expansion criteria; Not immediately re-starting enrollment
- **CRC cohort** - stage 1 fully enrolled
- **PD-(L)1 pretreated NSCLC cohort** - fully enrolled
- **Melanoma cohort** - Received regulatory input from FDA and MHRA on phase 3 trial

Upcoming data presentations at SITC (11/11)

- Stage 1 of PD-(L)1 Naïve and pretreated NSCLC
- Biomarker analysis of Stage 1 MEL patients

Encore 601: Enrollment complete for cohorts exploring combination in PD(L)-1 pretreated patients

Entinostat + KEYTRUDA®

Phase 2: Simon 2-stage design



^ *updated to include phase 1b patients; * Response defined as confirmed PR or CR*

Despite important advances, unmet need exists for melanoma patients



- 75-80% of Stage IV melanoma patients receive 1L PD-1 therapy^
- ~10,000 US patients* expected to require treatment after PD-1 antagonist

*Source: ^Kantar 2016 Treatment Architecture report; *Trial Trove, SEER data,*

Other ongoing Entinostat + PD-L1 combinations: ENCORE 602 and 603



Phase 2 ENDPOINTS:

- Primary endpoint - PFS
- Secondary endpoint - Overall response rate (ORR)
- Secondary endpoint - Overall survival (OS)

E2112: Phase 3 registration trial in advanced HR+, HER2- breast cancer

Exemestane +/- entinostat



ECOG-ACRIN cancer research group
Reshaping the future of patient care

PFS and OS co-primary endpoints

FDA BTD

- Data Safety Monitoring Committee (DSMC) completed PFS and 1st interim OS analysis
  - Results held confidentially by DSMC until enrollment completed
- Per ECOG-ACRIN, enrollment completion and sharing of PFS results expected 1H18
- Potential NDA filing 2018 based upon positive PFS data

Entinostat: Blockbuster potential as 2nd/3rd line therapy for HR+, HER2- metastatic breast cancer

First novel MOA in HR+ BC with Phase 3 data since CDK4/6

Leading treatment options – HR+, HER2- advanced breast cancer

1L

- CDK 4,6i + letrozole
- anastrozole or letrazole

~34,000 patients* go on to receive hormone therapy as a mono or combination regimen after 1st line therapy

2L+

- AFINITOR® + exemestane
- anastrazole
- Faslodex®
- entinostat + exemestane

Source: DataMonitor 2016 Breast cancer: HR+/HER2- Disease Coverage Report

SNDX-6352: Anti-CSF-1R Ab targeting TAMs to increase tumor infiltrating lymphocytes



- High affinity, IgG4 (K_D = 4-8 pM)
- Broad potential clinical utility

✓ Phase 1, single ascending dose (SAD) data at SITC

✓ Multiple ascending dose (MAD, solid tumors) trial initiated 3Q17
  - Enrollment of 1st cohort complete

TAM – tumor associated macrophage; CSF-1R – colony stimulating factor -1 receptor

Source : Ordentlich, P. et al SITC 2016

MLL rearrangements are oncogenic

MLL-r leukemia

- Diagnosis: leukemia with 11q23
- Incidence, major markets ~4,000/yr
  (60% adults: 40% peds)
- SOC: Induction (chemo) CR >90%
  Relapse rate ~50%
- 5 year survival < 40%
  (5 yr OS most ped leukemias > 85%)
- Bone marrow transplant
  only for <65 y.o.



MLL rearrangement (MLL-r)

Over 90 MLL fusion partners known;
9 account for >90% of rearrangements

Menin-MLL-r interaction required for transformation

- Assets block the binding of all MLL-r fusions to Menin
- Disruption of the Menin-MLL-r interaction may immediately impact gene transcription:
  - Decreasing cell proliferation
  - Increasing cell differentiation
  - Inducing apoptosis





MLL-r = rearrangements of the Mixed Lineage Leukemia (MLL) gene

Gene fusions from chromosomal rearrangements are very attractive molecular targets

- Genetic validation of target
- Precise patient selection
- Big effect in small studies
- Molecular marker of disease status
- Rapid regulatory path

BCR-ABL

gleevec (imatinib mesylate) tablets 100mg, 400mg

SPRYCEL dasatinib 100 mg tablets

ICLUSIG (ponatinib) tablets

Tasigna (nilotinib) 150mg, 200mg capsules

PML-RAR

VESANOID® (tretinoin) Capsules

EML4-ALK

ZYKADIA ceritinib 150 mg capsules

XALKORI CRIZOTINIB

ALUNBRIG™ BRIGATINIB 30 mg TABLETS

ALECENSA alectinib 150 mg capsules

NTRK

Larotrectinib (LOXO-101) *filed*

MLL-r



Potential use in multiple areas of unmet need and significant future value creation

Potential Future Indications

- MDS, ALL, AML (incl. *NPM1*^{mut} AML and MLL-PTD AML)
- CMML and CML
- Ewing's Sarcoma
- Pancreatic Cancer
- Gain-of-function p53 mutation tumors

Transaction follows Syndax recipe for value creation

- $5.0 million upfront
- $99 million in development and regulatory milestones
- $70 million in potential sales milestones
- Single digit royalties

Data presentations at SITC

Study	Description	Lead author / location
ENCORE 601: Entinostat – Pembro	Results from stage 1 of both PD-1 Naïve and PD-1 pretreated NSCLC cohorts	Leena Gandhi *11/11; 3:45pm* *Maryland Ballroom A*
ENCORE 601: Entinostat – Pembro	Biomarker analysis of PD-1 pretreated melanoma cohort	Melissa L. Johnson *11/11; 12:30-8:00pm* *Poster hall*
SNDX-6352: Monotherapy	Results of first in human, single ascending dose study in healthy volunteers	Renger G. Tiessen *11/10; 12:30-8:00pm* *Poster hall*

3Q17 Financial highlights and 2017 guidance

Ticker	SNDX (NASDAQ)	
As of September 30, 2017		
Cash and short-term investments[1]	$120.6 million	
Common shares O/S[2]	22.3 million	
2017 Operating Expense Guidance		
	Q4	2017
R&D[3]	$15-18 M	$47-50 M
Total Operating Expenses	$19-22 M	$63-66 M

1. *In October 2017 we earned $5.0 million milestone from KHK to be received in Q4 2017*
2. *In October 2017 we sold 2.0 million common shares to BVF with net proceeds of $24.8 million*
3. *R&D and Total Operating Expense includes the Q4 $5.0 million upfront license fee to Allergan*

Upcoming milestones

ENTINOSTAT (Class 1 specific HDAC inhibitor)	4Q17	1H18	2H18
ENCORE 601 - MEL (PD-1 pre-Tx) Phase 2 results		●	
ENCORE 601 - NSCLC (PD-1 pre-Tx) Phase 2 results		●	
ENCORE 601 – Go / No go decision on Stage 1 of MSS CRC cohort		●	
ENCORE 601 – complete EU reg. agency meetings re: MEL dev path	●		
E2112 - Per ECOG, complete Phase 3 enrollment; release PFS		●	
ENCORE 602 – Report TNBC results			●

SNDX-6352 (anti-CSF-1R mAB)	4Q17	1H18	2H18
Anticipate MAD trial data presentation (cancer patients)			●
Initiate phase 1b combination trial (cancer patients)			●

NEW Milestone

Syndax investment highlights

Entinostat

Combo with anti-PD-(L)1:

- Signals in Mel, NSCLC
- Ongoing NSCLC, Mel, TNBC, Ovar, CRC trials
- Multiple data readouts

FDA BTD

Combo with exemestane:

- Phase 3 data 1H18
- Japan pivotal initiated

SNDX-6352

CSF1R antibody:

- Phase 1 multiple ascending dose study ongoing
- Broad clinical dev program

NEW

Menin-MLLr inh

Onc driver specific:

- Targeting MLLr leukemias
- Preclinical dev. ongoing

Strong management team and cash position

CRC - colorectal cancer; NSCLC - non-small cell lung cancer; Mel - melanoma; TNBC - triple negative breast cancer; Ovar - ovarian cancer

Thank you. Questions?

Syndax